STENTiT resorbable fibrillated scaffold to reopen below-knee arteries

Study to Evaluate the Feasibility of the Resorbable Fibrillated Scaffold (RFS) in Arterial Lesions Below the Knee, in Patients With Critical Limb Ischemia

This first-in-human test will try a dissolving mesh tube (STENTiT RFS) to open below-knee arteries in people with critical limb ischemia.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 10 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Stentit (industry)
• Locations: 1 site (Graz)
• Trial ID: NCT07006467 on ClinicalTrials.gov

What this trial studies

This is a first-in-human feasibility trial of the STENTiT Resorbable Fibrillated Scaffold (RFS) for short below‑knee (infrapopliteal) lesions in patients with critical limb ischemia. Up to 10 subjects at a single investigational site will have the RFS implanted after lesion predilation, and other inflow or side‑branch lesions may be treated per standard of care. Primary safety is freedom from Major Adverse Limb Events (MALE) at 30 days, with additional safety and device performance endpoints collected through 24 months and technical success recorded at the time of implant. Vessel sizing (3.0–3.4 mm) will be guided by angiography and intravascular imaging to select appropriate candidates.

Who should consider this trial

Good fit: Adults (≥18) with critical limb ischemia Rutherford category 4 or 5 who have a single short (≤18 mm) target lesion in the tibioperoneal trunk or proximal anterior tibial, posterior tibial, or peroneal artery with vessel diameter 3.0–3.4 mm and at least one patent infrapopliteal branch are ideal candidates.

Not a fit: Patients with lesion length >18 mm, vessel diameters outside 3.0–3.4 mm, multiple untreated target lesions, or those unable to travel to the single study site are unlikely to benefit from this specific trial.

Why it matters

Potential benefit: If successful, the RFS could restore blood flow below the knee while avoiding permanent metal stents, potentially improving limb salvage and reducing long-term device-related issues.

How similar studies have performed: This is the first-in-human use of this specific RFS device; while bioresorbable scaffolds have been used in other vascular beds with mixed results, resorbable approaches for small below‑knee arteries remain largely unproven.

Eligibility criteria

Inclusion Criteria:

* General inclusion criteria:

  1. Subject must provide written informed consent prior to any clinical investigation related procedures.
  2. Subject is willing and able to comply with the study procedures, and follow-up schedule.
  3. Subject has Critical Limb Ischemia (CLI), Rutherford Becker Clinical Category 4 or 5
  4. Subject must be at least 18 years of age.

     Anatomical inclusion criteria:
  5. Target lesion located in the tibioperoneal trunk, or 2/3 proximal part of the anterior tibial artery, posterior tibial artery or peroneal artery.
  6. Only one target lesion per subject is included, other lesions can be treated per institution's standard of care.
  7. At least one infrapopliteal branch without an angiographic significant lesion (≥50% diameter stenosis by angiography).
  8. Vessel diameter of 3.0 mm to 3.4 mm. Quantitative imaging (IVUS and angiography) will be used to aid accurate sizing of the vessels.
  9. Target lesion length ≤ 18 mm.
  10. Target lesion of ≥70% diameter stenosis, per angiographic assessment at the time of the procedure.
  11. Target lesion is in an area that may be stented without blocking access to subject main branches, i.e ≥2 mm distanced from any bifurcation.
  12. Successful antegrade crossing of the target lesion

Exclusion Criteria:

* General exclusion criteria:

  1. Subject is currently participating in another clinical investigation that has not yet reached the primary endpoint.
  2. Pregnant or nursing subjects or with planned pregnancy during the clinical investigation follow-up period.
  3. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements.
  4. Incapacitated individuals, as defined as persons who are mentally ill, mentally handicapped, or individuals without legal authority, are excluded from the study population.
  5. Subject has known hypersensitivity or contraindication to device material and its degradants (poly (L-lactide), poly (glycolic acid), lactic acid, and glycolic acid) that cannot be adequately pre-medicated. Subject has known contrast sensitivity that cannot be adequately pre-medicated.
  6. Subject has known allergy hypersensitivity or contraindication to aspirin; or to ADP antagonists such clopidogrel, prasugrel or ticagrelor; or to anticoagulants such as heparin or bivalirudin, and therefore cannot be adequately treated with study medications.
  7. Subject with planned surgery or procedure necessitating discontinuation of antiplatelet medications, within 3 months after index procedure.
  8. Subject has life expectancy ≤ 1 year.
  9. Subject has had a stroke within the previous 3 months with residual Rankin score of ≥2.
  10. Subject has renal insufficiency as defined as an estimated GFR \< 30ml/min per 1.73m2
  11. Subject has platelet count \< 100,000 cells/mm3 or \> 700,000 cells/mm3, a WBC \< 3,000 cells/mm3, or hemoglobin \< 9.0 g/dl.
  12. Subject has known serious immunosuppressive disease (e.g. human immunodeficiency virus), or has severe autoimmune disease, that requires chronic immunosuppressive therapy (e.g. systemic lupus erythematosus, etc.), or subject is receiving immunosuppression therapy for other conditions. Subjects treated for HIV (Human Immunodeficiency Virus) and who have undetectable viral load, such that their immune system is not considered compromised, are eligible.
  13. Subject has Body Mass Index (BMI) \< 18.
  14. Subject has a known coagulation disorder with increased risk of arterial thrombosis. Subject with deep vein thrombosis and disorders that increase the risk of deep vein thrombosis can be included in the study.
  15. Subject who requires thrombolysis as a primary treatment modality or requires other treatment for acute limb ischemia of the target limb.
  16. Subject has previously had or requires surgical revascularization involving any vessel of the ipsilateral extremity.
  17. Subject has signs or symptoms of advanced limb infection or septicemia (fever \> 38.5 degrees Celsius, WBC \> 15,000 cells/microliter, hypotension) at the time of assessment.
  18. Subject with extensive tissue loss salvageable only with complex foot reconstruction or non-traditional transmetatarsal amputation.

      Anatomic exclusion criteria:
  19. Subject has tandem lesions at the target lesion site (plaque free zone \< 2 cm)
  20. Pre-dilatation of the target lesion at the time of study intervention did not reach \<50% residual diameter stenosis by angiography.
  21. Target lesion that has prior metallic stent implant.
  22. Failed PTA of target lesion ≤ 60 days prior to the procedure date.
  23. The target vessel has another significant lesion (≥50% diameter stenosis by angiography).
  24. Significant stenosis (≥50% stenosis) lesion in a distal outflow artery that would be perfused by the target vessel and that requires treatment at the time of the index procedure.
  25. Subject has angiographic evidence of, thrombus, thromboembolism or atheroembolism in the ipsilateral extremity.
  26. Unsuccessfully treated proximal inflow limiting arterial stenosis or inflow-limiting arterial lesions left untreated.
  27. Aneurysm in the iliac, common femoral, superficial femoral, popliteal or target artery of the ipsilateral extremity.
  28. Target lesion has a high probability that atherectomy will be required at the time of index procedure for treatment of the target vessel.

Where this trial is running

Graz

• Medical Universiteit Graz — Graz, Austria (RECRUITING)

Study contacts

• Study coordinator: Kim van Noort, PhD

Conditions: Critical Limb Ischemia